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Cochrane Collaborative Review Group on Peripheral
Vascular Diseases: Review AbstractsIntroduction
The following abstracts are part of an ongoing
series of articles produced by the Cochrane
Collaborative Review Group on Peripheral Vascular
Diseases, which is part of the Cochrane Collabor-
ation. The reviews are published in full on The
Cochrane Library, a quarterly electronic journal
available on CD-ROM and via the Internet. The
electronic format allows Cochrane reviews to
accommodate new data as they become available,
making the library a consistently up-to-date source
of information over time.
Certain abstracts appearing on The Cochrane Library
may be presented in a simpler, less scientific format
than the abstracts presented here to permit greater
accessibility to the public. However, the substance of
both versions is the same. Cochrane reviews are now
indexed on MEDLINE.
If you are interested in conducting a Cochrane
review or contributing to the activities of the Cochrane
Peripheral Vascular Diseases Group please contact:
Professor FGR Fowkes
Cochrane Collaborative Review Group on
Peripheral Vascular Diseases
Public Health Sciences
University of Edinburgh
Teviot Place
Edinburgh EH8 9AG
Tel.: C44 (0) 131 650 3220
Fax: C44 (0) 131 650 6904Any comments or criticisms on Cochrane reviews/
abstracts should be made through the comments/0018+ 04 $35.00/0criticisms facility on The Cochrane Library, or by
contacting the group at the above address.
Abstracts
Abstract. Non-pharmaceutical measures for preven-
tion of post-thrombotic syndrome.
D.N. Kolbach, M.W.C. Sandbrink, K. Hamulyak,
H.A.M. Neumann, M.H. Prins
First Published: The Cochrane Library Issue 1, 2004Background
Post-thrombotic syndrome (PTS) is a long-term com-
plication of deep vein thrombosis characterised by
chronic pain, swelling, and skin changes in the affected
limb. One in every three patients with deep vein
thrombosis will develop post-thrombotic compli-
cations within five years.Objectives
The objective of this review was to determine the
relative effectiveness of, and the rate of complications
using non-pharmaceutical interventions in patients
with deep vein thrombosis in the prevention of post-
thrombotic syndrome.Search strategy
The reviewers searched the Cochrane Peripheral
Vascular Diseases Group Specialised Trials Register
(last searched January 2003), and the Cochrane Central
Register of Controlled Trials (CENTRAL) (last
searched Issue 4, 2002). In addition, journals, con-
ference proceedings and bibliographies were handEur J Vasc Endovasc Surg 29, 18–21 (2005)
doi:10.1016/j.ejvs.2004.10.001, available online at http://www.sciencedirect.com on
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involved in the clinical area was also sought.Selection criteria
Randomised controlled trials of non-pharmaceutical
interventions, such as bandaging and elastic stockings
in patients with clinically confirmed deep vein
thrombosis were eligible for inclusion. The primary
outcome was the occurrence of PTS. There was no
restriction on date or language. One reviewer ident-
ified and assessed titles and abstracts for relevance.
These were verified independently by a second
reviewer.Data collection and analysis
Data extraction was undertaken independently by two
reviewers using data extraction sheets.Main results
Three randomised controlled trials that evaluated
compression therapy were identified. Two studies
compared elastic compression stockings (pressure of
30 to 40 mm Hg at the ankle) with no intervention
applied directly after an episode of deep vein throm-
bosis. The other small study compared elastic com-
pression stockings (pressure 20 to 30 mm Hg) with
stockings that were one to two sizes too large in
patients one year after an episode of deep vein
thrombosis. Overall, in the treatment group at two
years, the use of elastic compression stockings was
associated with a highly statistically significant
reduction in the incidence of PTS (odds ratio (OR)
0.31; 95% confidence interval (CI) 0.20 to 0.48). In
addition, the incidence of severe PTSwas reduced from
OR 0.39 (95% CI 0.20 to 0.76). In another randomised
controlled trial that considered the first nine days post
deep vein thrombosis, no difference was found in the
incidence of pulmonary embolism and size of throm-
bus in the femoral vein. A statistically significant
reduction (p!0.05) was found in pain, swelling and
clinical scores, favouring the compression group.Reviewers’ conclusions
There is substantial evidence that elastic compression
stockings reduce the occurrence of post-thrombotic
syndrome after deep vein thrombosis. No seriousadverse effects were mentioned in the studies. Hence,
elastic compression stockings should be added to the
treatment of deep vein thrombosis to prevent the
development of post-thrombotic syndrome.Abstract. Compression therapy for treating stage I
and II (Widmer) post-thrombotic syndrome.
D.N. Kolbach, M.W.C. Sandbrink, H.A.M.
Neumann, M.H. Prins
First Published: The Cochrane Library Issue 4, 2003Background
Post-thrombotic syndrome (PTS) is a long-term com-
plication of deep vein thrombosis characterised by
chronic complaints, swelling, and skin changes in the
affected limb. One in every three patients with deep
vein thrombosis develops post-thrombotic compli-
cations within five years.Objectives
The objective of this review was to assess the
effectiveness of compression therapy in patients with
stage I and II post-thrombotic syndrome according to
the classification of Widmer. Interventions of interest
included elastic compression stockings and mechan-
ical devices, compared with no intervention, and with
each other.Search strategy
The reviewers searched the Cochrane Peripheral
Vascular Diseases Specialised Trials Register (last
searched April 2003), and the Cochrane Central
Register of Controlled Trials (CENTRAL) (last
searched Issue 1, 2003). In addition, journals, con-
ference proceedings and bibliographies were hand
searched. Personal contact with other investigators
involved in the clinical area was sought to get
information about missed or unpublished studies.Selection criteria
Trials that evaluated compression therapy for stage I
and II (Widmer) post-thrombotic syndrome were
considered for inclusion. Primary outcomes were leg
ulceration, or deterioration of post-thrombotic syn-
drome. There were no restrictions on date or language.Eur J Vasc Endovasc Surg Vol 29, January 2005
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evance. This was verified independently by a second
reviewer.Data collection and analysis
Details of eligible studies were extracted and sum-
marised using data extraction sheets. Data extraction
was undertaken by one reviewer and verified by a
second reviewer.Main results
Only two trials were identified that addressed physi-
cal treatment of post-thrombotic syndrome. Both trials
were initiated by the same group of investigators. A
cross-over study lasting two months compared low
and high pressure with intermittent compression units
for severe post-thrombotic syndrome. This showed a
beneficial effect of higher pressures. The second study,
in patients with mild to moderate post-thrombotic
symptoms, showed no effect of elastic compression
stockings (30–40 mm Hg at the ankle region) when
compared to ’placebo’ stockings that were one to two
sizes too large.Reviewers’ conclusions
There is some evidence of a beneficial effect of
intermittent pneumatic compression units, but the
study was too small and of too short a duration to
draw strong conclusions. Further research is needed in
order to assess whether intermittent pneumatic com-
pression units give long term reduction and relief of
the symptoms caused by post-thrombotic syndrome,
and prevent deterioration and leg ulceration. The use
of elastic compression stockings to treat post-throm-
botic syndrome cannot be supported on the basis of
the currently available data.Abstract. Intravenous immunoglobulin for the treat-
ment of Kawasaki disease in children.
R.M. Oates-Whitehead, J.H. Baumer, L. Haines, S.
Love, I.K. Maconochie, A. Gupta, K. Roman, J.S. Dua,
I. Flynn
First Published: The Cochrane Library Issue 4, 2003Eur J Vasc Endovasc Surg Vol 29, January 2005Background
Kawasaki disease is the most common cause of
acquired heart disease in children in developed
countries. The coronary arteries supplying the heart
can be damaged in Kawasaki disease. The principal
advantage of timely diagnosis is the potential to
prevent this complication with early treatment. Intra-
venous immunoglobulin (IVIG) is widely used for this
purpose.Objectives
The objective of this review was to evaluate the
effectiveness of IVIG in treating, and preventing
cardiac consequences, of Kawasaki disease in children.Search strategy
Electronic searches of the Cochrane Peripheral Vascu-
lar Disease Group Specialised Register (last searched
March 2003), the Cochrane Central Register of Con-
trolled Trials (CENTRAL) (last searched Issue 1, 2003),
MEDLINE, EMBASE, and CINAHL were performed
(last searched April 2003). We also searched references
from relevant articles and contacted authors where
necessary. In addition, we contacted experts in the
field for unpublished works.Selection criteria
Randomised controlled trials of intravenous immuno-
globulin to treat Kawasaki disease were eligible for
inclusion.Data collection and analysis
Fifty-nine trials were identified in the initial search. On
careful inspection only sixteen of these met all the
inclusion criteria. Trials were data extracted and
assessed for quality by at least two reviewers. Data
were combined for meta-analysis using relative risk
ratios for dichotomous data or weighted mean
difference for continuous data. A random effects
statistical model was used.Main results
The meta-analysis of IVIG versus placebo, including
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coronary artery abnormalities (CAAs) in favour of
IVIG, at thirty days (relative risk (RR) 0.74; 95%
confidence interval (CI) 0.61 to 0.90). No statistically
significant difference was found thereafter. A sub-
group analysis excluding children with CAAs at
enrolment also found a significant reduction of new
CAAs in children receiving IVIG (RR 0.67; 95% CI 0.46
to 1.00). There was a trend towards benefit from IVIG
at sixty days (pZ0.06).
Results of dose comparisons showed a decrease in
the number of new CAAs with increased dose. The
meta-analysis of 400 mg/kg/day for five days versus
2 gm/kg in a single dose showed statistically signifi-
cant reduction in CAAs at thirty days (RR 4.47; 95% CI
1.55 to 12.86). This comparison also showed a
significant reduction in duration of fever with the
higher dose.
There was no statistically significant difference
noted between different preparations of IVIG.
There was no statistically significant difference of
adverse effects in any group.Reviewers’ conclusions
Children fulfilling the diagnostic criteria for Kawasaki
disease should be treated with IVIG (2 gm/kg single
dose) within 10 days of onset of symptoms.Abstract. Treatment of hypertension in peripheral
arterial disease.
G.Y.H. Lip, A.J.Makin
First Published: The Cochrane Library Issue 4, 2003Background
Peripheral arterial disease (PAD) causes considerable
morbidity and mortality. Hypertension is a risk factor
for PAD. Therefore, treatment for hypertension must
be compatible with the symptoms of PAD. Contro-
versy regarding the effects of beta blockade for
hypertension in patients with PAD has led many
physicians to stop prescribing beta-blockers. Little is
known about the effects of other classes of anti-
hypertensive drugs in the presence of PAD.Objectives
To determine the effects of anti-hypertensive drugs on:† cardiovascular events and death in patients with
hypertension and PAD;† symptoms of claudication and critical leg
ischaemia;† progression of PAD, and revascularisation, or
amputations.Search strategy
Trials were sought via the Specialised Register of the
Cochrane Peripheral Vascular Diseases Group (last
searched July 2003), the Cochrane Central Register of
Controlled Trials (CENTRAL) (last searched Issue 2,
2003), and the NHS Database of Abstracts of Reviews
of Effectiveness (DARE) (last searched August 2002).
Abstracts of cardiology meetings and reference lists of
papers were also examined. There were no language
restrictions.Selection criteria
Randomised controlled trials of at least one anti-
hypertensive treatment against placebo, or two anti-
hypertensive medications against each other, with
interventions lasting at least one month were con-
sidered for inclusion. Trials had to include patients
with symptomatic PAD. Trials of poor quality and
execution were excluded, as were cross-over trials.Data collection and analysis
Data were extracted by one reviewer and checked by
the other. Eligible studies were excluded when
presentation prevented adequate extraction of data,
and enquiries to authors did not yield the raw data.Main results
Two studies were included in the review. In one trial
using perindopril in small numbers of patients with
PAD, there was a marginal increase in claudication
distance (weighted mean difference (WMD) 8.0; 95%
confidence interval (CI)K30.66 to 46.66), but no change
in ankle brachial pressure index (ABPI), (WMD 0; 95%
CIK0.14 to 0.14), and a reduction in walking distance
(WMDK46; 95% CIK169.24 to 77.24).
In patients undergoing angioplasty, a second trial
suggested that the calcium antagonist verapamil
reduced restenosis, although this was not reflected in
the maintenance of a high ABPI.Eur J Vasc Endovasc Surg Vol 29, January 2005
